Sangamo Therapeutics (SGMOQ) Share-based Compensation (2010 - 2025)

Sangamo Therapeutics has reported Share-based Compensation for 16 years, with the latest figure at $2.1 million in Q4 2025.

• On a quarterly basis, Share-based Compensation fell 35.12% year-over-year to $2.1 million in Q4 2025; TTM through Dec 2025 was $9.1 million, a 26.68% decrease from a year earlier, with the FY2025 full-year figure at $9.1 million, down 26.68% from the prior year.
• Share-based Compensation was $2.1 million for Q4 2025 at Sangamo Therapeutics, roughly flat from $2.1 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.5 million in Q2 2021, with the low at $2.1 million in Q3 2025.
• Average Share-based Compensation over 5 years is $5.7 million, with a median of $6.5 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Share-based Compensation soared 40.2% in 2021, then tumbled 67.15% in 2024.
• Over 5 years, Share-based Compensation stood at $8.1 million in 2021, then climbed by 2.13% to $8.2 million in 2022, then dropped by 25.96% to $6.1 million in 2023, then tumbled by 46.24% to $3.3 million in 2024, then plunged by 35.12% to $2.1 million in 2025.
• The last three Share-based Compensation figures came in at $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.